Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aducanumab for Early-stage Alzheimer's Disease
ChiCTR2200066153Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aducanumab in Alzheimer's disease (AD), sponsored by Ruijin Hospital. Primary endpoints: Mini-Mental State Examination (MMSE) score, Alzheimer's Disease Rating Scale Cognitive Scale (ADAS-Cog) score and 1 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2200066153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066153.